Abstract:More than two hundred individuals developed Creutzfeldt-Jakob disease (CJD) worldwide as a result of treatment, typically in childhood, with human cadaveric pituitary-derived growth hormone contaminated with prions. Although such treatment ceased in 1985, iatrogenic CJD (iCJD) continues to emerge because of the prolonged incubation periods seen in human prion infections. Unexpectedly, in an autopsy study of eight individuals with iCJD, aged 36-51 years, in four we found moderate to severe grey matter and vascular amyloid-β (Aβ) pathology. The Aβ deposition in the grey matter was typical of that seen in Alzheimer's disease and Aβ in the blood vessel walls was characteristic of cerebral amyloid angiopathy and did not co-localize with prion protein deposition. None of these patients had pathogenic mutations, APOE ε4 or other high-risk alleles associated with early-onset Alzheimer's disease. Examination of a series of 116 patients with other prion diseases from a prospective observational cohort study showed minimal or no Aβ pathology in cases of similar age range, or a decade older, without APOE ε4 risk alleles. We also analysed pituitary glands from individuals with Aβ pathology and found marked Aβ deposition in multiple cases. Experimental seeding of Aβ pathology has been previously demonstrated in primates and transgenic mice by central nervous system or peripheral inoculation with Alzheimer's disease brain homogenate. The marked deposition of parenchymal and vascular Aβ in these relatively young patients with iCJD, in contrast with other prion disease patients and population controls, is consistent with iatrogenic transmission of Aβ pathology in addition to CJD and suggests that healthy exposed individuals may also be at risk of iatrogenic Alzheimer's disease and cerebral amyloid angiopathy. These findings should also prompt investigation of whether other known iatrogenic routes of prion transmission may also be relevant to Aβ and other proteopathic seeds associated with neurodegenerative and other human diseases.

Ist Alzheimer-Demenz übertragbar?

Peptides That Form Amyloid Plaques in Alzheimer's May Be Transmissible, Study Finds.

Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone

Evidence for iatrogenic transmission of Alzheimer's disease

Signs of 'transmissible' Alzheimer's seen in people who received growth hormone

Daily briefing: New evidence supports controversial hypothesis of ‘transmissible’ Alzheimer’s

Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy

Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β-amyloid

Structural biology of cell surface receptors implicated in Alzheimer’s disease

Current viral-mediated gene transfer research for treatment of Alzheimer’s disease

Neuron-to-Neuron Transmission of Neurodegenerative Pathology

Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe

Infectious agents and Alzheimer's disease

Genetics impact risk of Alzheimer’s disease through mechanisms modulating structural brain morphology in late life

Alzheimer's disease as a viral disease: Revisiting the infectious hypothesis

Demenzprävention

Beta-Amyloid Related Neurodegenerative and Neurovascular Diseases: Potential Implications for Transfusion Medicine

Smartphone-App entdeckt frühe Demenz

Degenerative diseases of the central nervous system transmissible to experimental animals

Alzheimer's disease.

Intracerebral inoculation of healthy non-transgenic rats with a single aliquot of oligomeric amyloid-β (1-42) profoundly and progressively alters brain function throughout life